Work

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer

Year: 2016

Type: article

Abstract: Grade 1 Topical metronidazole, oral doxycycline (100 mg/day) Complete resolution c No a Following National Cancer Institute CTCae V4.02.b erythemato-telangiectatic rosacea.c 4 and 8 weeks after the last dose of nivolumab, respectively.

Source: Acta Dermato Venereologica

DOI: 10.2340/00015555-2566

Authors: E Bousquet, A Zarbo, E Tournier, C Chevreau, J Mazieres, M Lacouture, V Sibaud

Institutions: Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Université de Toulouse

Language: English

Topic: Acne and Rosacea Treatments and Effects

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,725

Funders: Amgen, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Les Laboratories Pierre Fabre, Galderma, National Institutes of Health, Genentech, National Cancer Institute

Awards: G4102770861, G6319821752, G9000003249, Cancer Center Support Grant

OpenAlex ID: W2550772903

FWCI: 1.309

Cites: 10

Cited by: 20

Related to: 10